Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Soleno Therapeutics (SLNO) Operating Margin (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Operating Margin for 5 consecutive years, with 43.15% as the latest value for Q4 2025.

  • On a quarterly basis, Operating Margin changed N/A to 43.15% in Q4 2025 year-over-year; TTM through Dec 2025 was 5.34%, a N/A change, with the full-year FY2025 number at 4.94%, down 8123791.0% from a year prior.
  • Operating Margin was 43.15% for Q4 2025 at Soleno Therapeutics, up from 31.75% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 3360.98% in Q1 2025 to a low of 31.75% in Q3 2025.